In addition, cerebrospinal fluid (CSF) Aβ and tau have been considered as core biomarkers of AD in clinical diagnosis and research framework (Blennow, 2017); the decrease of Aβ peptide (i.e., Aβ42/40) and the increase of tau protein (i.e., threonine P-tau181) are commonly reported as potential CSF indicators of AD dementia (Andreasen et al., 1999; Ashton et al., 2022). Here, MAPT is linked to Alzheimer disease.